198 related articles for article (PubMed ID: 23687950)
1. Advances in the development and use of human tissue-based techniques for drug toxicity testing.
Clotworthy M; Archibald K
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1155-69. PubMed ID: 23687950
[TBL] [Abstract][Full Text] [Related]
2. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
3. Investigative safety science as a competitive advantage for Pharma.
Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
[TBL] [Abstract][Full Text] [Related]
4. Dogs and monkeys in preclinical drug development: the challenge of reducing and replacing.
Pellegatti M
Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1171-80. PubMed ID: 23705836
[TBL] [Abstract][Full Text] [Related]
5. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
6. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
7. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates.
Kramer JA; Sagartz JE; Morris DL
Nat Rev Drug Discov; 2007 Aug; 6(8):636-49. PubMed ID: 17643090
[TBL] [Abstract][Full Text] [Related]
8. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
9. Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.
Greene N; Song M
Future Med Chem; 2011 Sep; 3(12):1503-11. PubMed ID: 21882943
[TBL] [Abstract][Full Text] [Related]
10. Innovation in safety pharmacology testing.
Pugsley MK; Towart R; Authier S; Gallacher DJ; Curtis MJ
J Pharmacol Toxicol Methods; 2011; 64(1):1-6. PubMed ID: 21640842
[TBL] [Abstract][Full Text] [Related]
11. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
12. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
13. Emerging technologies and challenges for better and safer drugs.
Theodosiou M; Amir-Aslani A; Mégarbane B
Biotechnol Lett; 2014 Apr; 36(4):677-84. PubMed ID: 24243233
[TBL] [Abstract][Full Text] [Related]
14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
15. Biomedical imaging in the safety evaluation of new drugs.
Wang YX; Yan SX
Lab Anim; 2008 Oct; 42(4):433-41. PubMed ID: 18782821
[TBL] [Abstract][Full Text] [Related]
16. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
17. Retinal and ocular toxicity in ocular application of drugs and chemicals--part I: animal models and toxicity assays.
Penha FM; Rodrigues EB; Maia M; Dib E; Fiod Costa E; Furlani BA; Nunes Moraes Filho M; Dreyfuss JL; Bottós J; Farah ME
Ophthalmic Res; 2010; 44(2):82-104. PubMed ID: 20484950
[TBL] [Abstract][Full Text] [Related]
18. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
Sartipy P; Björquist P
Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
[TBL] [Abstract][Full Text] [Related]
19. Improving toxicity screening and drug development by using genetically defined strains.
Festing MF
Methods Mol Biol; 2010; 602():1-21. PubMed ID: 20012389
[TBL] [Abstract][Full Text] [Related]
20. Zebrafish for drug toxicity screening: bridging the in vitro cell-based models and in vivo mammalian models.
Sukardi H; Chng HT; Chan EC; Gong Z; Lam SH
Expert Opin Drug Metab Toxicol; 2011 May; 7(5):579-89. PubMed ID: 21345150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
